Vnitr Lek 2009, 55(7-8):653-658

Metabolic syndrome and cardiovascular disease

J. ©pinar1,*, J. Vítovec2
1 Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviątě Bohunice, přednosta prof. MUDr. Jindřich ©pinar, CSc., FESC
2 I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC

We provide an overview of the current views on the association between metabolic syndrome and cardiovascular disease. Insulin resistance, frequently onsetting from obesity and associated hypercholesterolemia, hypertension and diabetes mellitus, is the common denominator. We also highlight another risk factor - heart rate, closely related to the prognosis of healthy individuals, patients with hypertension and patients following myocardial infarction. Finally, we present the results of the CRUSADE study that has clearly described the association between obesity and age and the first manifestation of the ischemic heart disease.

Keywords: metabolic syndrome; diabetes mellitus; hypertension; heart rate; obesity

Received: March 23, 2009; Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, Vítovec J. Metabolic syndrome and cardiovascular disease. Vnitr Lek. 2009;55(7-8):653-658.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480. Go to original source... Go to PubMed...
    2. Berková M. Sledování diastolického plnění levé komory srdeční u diabetiků 1. typu a srovnání diastolických ukazatelů s ukazateli kardiální autonomní neuropatie. Kandidátská disertační práce. Olomouc 2003: 108.
    3. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572. Go to original source... Go to PubMed...
    4. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497. Go to original source... Go to PubMed...
    5. Gillman MW, Kannel WB, Belanger A et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-1154. Go to original source... Go to PubMed...
    6. Charvát J, Hlaváček K, Vaněček T et al. Výsledky koronarografických nálezů a prognóza nemocných s diabetes mellitus a ischemickou chorobou srdeční. Cor vasa 2001; 43: 483-487.
    7. Chlumský J. Vliv kompenzace diabetu na diastolické plnění levé komory. Vnitř Lék 1994; 40: 93-95. Go to PubMed...
    8. Kanel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham Study. Am J Cardiol 1974; 34: 29-34. Go to original source... Go to PubMed...
    9. Kanel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care 1979; 2: 120-126. Go to original source... Go to PubMed...
    10. Maarten L, Simoons MD, Bonneux L. Obesity, cardiology and beyond. J Am Coll Cardiol 2008; 52: 986-987. Go to original source...
    11. Madala MC, Franklin BA, Chen AY et al. Obesity and age of first non ST segment elevation myocardial infarction. J Am Coll Cardiol 2008; 52: 979-985. Go to original source... Go to PubMed...
    12. Niles NW, McGrath PD, Malenka D et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularisation. Results from a large regional prospective study. J Am Coll Cardiol 2001; 37: 1008-1015. Go to original source... Go to PubMed...
    13. Norhammar A, Malmberg K. Heart failure and glucose abnormalities: an increasing combination with poor functional capacity and outcome. Eur Heart J 2000; 21: 1293-1294. Go to original source... Go to PubMed...
    14. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997; 11 (Suppl 1): S19-S27.
    15. Peruąičová J. Diabetické makroangiopatie a mikroangiopatie. Praha: Galén 2003.
    16. Stratton IM, Adler AI, Neil HA et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observentional study. BMJ 2000; 321: 405-412. Go to original source... Go to PubMed...
    17. Suskin N, McKelvie RS, Burns RJ. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000; 21: 1368-1375. Go to original source... Go to PubMed...
    18. Swan JW, Walton C, Godsland I et al. Insulin resistance in chronic heart failure. Eur Heart J 1994; 15: 1528-1532. Go to original source... Go to PubMed...
    19. ©pinar J, Vítovec J. Přehled nejvýznamnějąích studií u hypertenze a diabetes mellitus. Vnitř Lék 1999; 45: 677-679. Go to PubMed...
    20. ©pinarová L, Toman J, Meluzín J et al. Diabetes mellitus u chronického srdečního selhání. Cor Vasa 2003: 45: 96.
    21. The UKPDS investigators: UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes. Lancet 1998; 352: 837-865. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.